12th-14th September, 2016
September 12, 2016
14:00 - 17:00
Rethinking the Amyloid Beta Cascade Hypothesis & its Targeting for Disease Modification in Alzheimer’s Disease
Vice President, Distinguished Research Fellow, Foundational Neuroscience Center, AbbVie
Since its inception, the amyloid beta cascade hypothesis has provided the theoretical base for Alzheimer’s pathogenesis, and has consequently dominated R&D efforts in the neurodegenerative field. However, despite the enormous investment in targeting amyloid, no candidates have proved effective in treating disease progression. This has led to a rethinking of the role of amyloid accumulation in the initiation and development of Alzheimer’s. This interactive workshop will discuss in-depth the following topics:
- Critically reviewing and analysing of the role of the amyloid beta cascade in neurodegenerative pathology
- Amyloid beta plaques: cause or consequence?
- Fully elucidating the amyloid beta cascade “timeline” in Alzheimer’s disease progression: What are the triggers and how does amyloid loading impact different stages of disease progression?
- Building on our new view of the amyloid cascade to devise novel therapeutics to target and treat amyloid loading in the brain
Eric Karran, Vice President, Distinguished Research Fellow, Foundational Neuroscience Center, AbbVie